STARTER checklist for antimalarial therapeutic efficacy reporting
Malaria Journal volume 21, Article number: 187 (2022)
Efficacious antimalarials are a cornerstone of the global effort to control and eliminate malaria. However, the spread of drug resistance threatens gains achieved over the early years of this century. Of particular concern is widespread artemisinin resistance in Southeast Asia and its recent emergence in Africa, threatening the efficacy of artemisinin-based combination therapies that currently offer our best treatments for malaria . Prompt identification of the emergence and spread of antimalarial drug resistance is crucial to guarantee effective case management. At a country level, efficacy data are used by ministries of health and their partners to determine national treatment guidelines. Because parasites do not respect political and administrative boundaries, coordination of surveillance and control strategies at the regional and global level is necessary to guide larger containment strategies.
Since the 1960s, the foundation of antimalarial drug efficacy monitoring has been the use of therapeutic efficacy studies that monitor parasitological and clinical response in patients treated for malaria. Standardized methods for performance and analysis of these studies are codified in World Health Organization (WHO) guidance documents [2,3,4]. Despite the standardized guidance, recent investigation has identified frequent non-adherence to the WHO guidelines [1, 5]. Notably, deviations from the standard of practice methodology are common, particularly related to analysis of genotyping data and definition of primary outcome indicators, and critical methodological details are often omitted from publications reporting efficacy data. As a consequence, there is the risk that reported efficacy could either be underestimated or overestimated, with readers not able to determine both the scope and the direction of the under- or overestimates. Such a loss in accuracy can obstruct the global effort to prevent and contain antimalarial drug resistance.
Incorporating comments from the WHO Global Malaria Programme, the Malaria Branch of the Centers for Disease Control and Prevention, the US President’s Malaria Initiative, and the editors-in-chief and antimalarial efficacy section leads from the American Journal of Tropical Medicine and Hygiene and Malaria Journal, we have developed the Standardized Antimalarial Therapeutic Efficacy Reporting (STARTER) Checklist, which lays out best practices for reporting results of antimalarial efficacy studies. Similar to other reporting checklists, it has been registered and is available at the EQUATOR Network repository  (Table 1).
We emphasize that checklists are not replacements for peer-review , but rather tools to promote uniformity in reporting. Filling out the checklist does not substitute for careful adherence to the global WHO standards for efficacy trials. Efficacy trial investigators and sponsors that follow WHO’s guidance and verify their adherence at the protocol development, implementation, analysis, and reporting stages will likely find the STARTER checklist facilitates their manuscript development.
World Health Organization. Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010–2019). Geneva: World Health Organization; 2020.
World Health Organization. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009.
World Health Organization. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. Geneva: World Health Organization; 2007.
World Health Organization. Informal consultation on methodology to distinguish reinfection from recrudescence in high malaria transmission areas. Geneva: World Health Organization; 2021.
Plucinski M, Hastings I, Moriarty LF, Venkatesan M, Felger I, Halsey ES. Variation in calculating and reporting antimalarial efficacy against Plasmodium falciparum in Sub-Saharan Africa: a systematic review of published reports. Am J Trop Med Hyg. 2021. https://doi.org/10.4269/ajtmh.20-1481.
The EQUATOR Network | Enhancing the quality and transparency of health research. UK: The EQUATOR Network; 2021.
Hirji KF. No short-cut in assessing trial quality: a case study. Trials. 2009;10:1.
The authors thank Pascal Ringwald at the WHO Global Malaria Programme and Marcel Hommel at Malaria Journal for their comments and review.
ESH, MMP, and MV are supported by the U.S. President’s Malaria Initiative. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. EAA and QB are Associate Editors at the Malaria Journal. PJR is the AJTMH Editor-in-Chief.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is co-published by the American Journal of Tropical Medicine and Hygiene and Malaria Journal.
About this article
Cite this article
Plucinski, M.M., Ashley, E.A., Bassat, Q. et al. STARTER checklist for antimalarial therapeutic efficacy reporting. Malar J 21, 187 (2022). https://doi.org/10.1186/s12936-022-04182-x